News Home

Should You Buy Smith & Nephew plc (SNN) Stock on Thursday?

Thursday, August 18, 2022 10:33 AM | InvestorsObserver Analysts
Should You Buy Smith & Nephew plc (SNN) Stock on Thursday?

The market has been down on Smith & Nephew plc (SNN) stock recently. SNN gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Smith & Nephew plc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SNN!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With SNN Stock Today?

Smith & Nephew plc (SNN) stock is trading at $25.09 as of 10:29 AM on Thursday, Aug 18, a drop of -$0.26, or -1.03% from the previous closing price of $25.35. The stock has traded between $25.01 and $25.21 so far today. Volume today is light. So far 163,004 shares have traded compared to average volume of 1,085,060 shares.

More About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder. Click Here to get the full Stock Report for Smith & Nephew plc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App